GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » PE Ratio (TTM)

Applied Genetic Technologies (Applied Genetic Technologies) PE Ratio (TTM) : At Loss (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), Applied Genetic Technologies's share price is $0.3936. Applied Genetic Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.42. Therefore, Applied Genetic Technologies's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Applied Genetic Technologies's PE Ratio (TTM) or its related term are showing as below:

AGTC' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 19.93   Max: 545
Current: At Loss


During the past 11 years, the highest PE Ratio (TTM) of Applied Genetic Technologies was 545.00. The lowest was 0.00. And the median was 19.93.


AGTC's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 26.82 vs AGTC: At Loss

Applied Genetic Technologies's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.28. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.42.

As of today (2024-04-26), Applied Genetic Technologies's share price is $0.3936. Applied Genetic Technologies's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.42. Therefore, Applied Genetic Technologies's PE Ratio without NRI for today is At Loss.

During the past 11 years, Applied Genetic Technologies's highest PE Ratio without NRI was 545.00. The lowest was 0.00. And the median was 19.93.

Applied Genetic Technologies's EPS without NRI for the three months ended in Sep. 2022 was $-0.28. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.42.

During the past 3 years, the average EPS without NRI Growth Rate was -140.50% per year.

During the past 11 years, Applied Genetic Technologies's highest 3-Year average EPS without NRI Growth Rate was 59.50% per year. The lowest was -140.50% per year. And the median was -1.75% per year.

Applied Genetic Technologies's EPS (Basic) for the three months ended in Sep. 2022 was $-0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.42.


Applied Genetic Technologies PE Ratio (TTM) Historical Data

The historical data trend for Applied Genetic Technologies's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies PE Ratio (TTM) Chart

Applied Genetic Technologies Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Applied Genetic Technologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Applied Genetic Technologies's PE Ratio (TTM)

For the Biotechnology subindustry, Applied Genetic Technologies's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Genetic Technologies's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Applied Genetic Technologies's PE Ratio (TTM) falls into.



Applied Genetic Technologies PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Applied Genetic Technologies's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.3936/-1.420
=At Loss

Applied Genetic Technologies's Share Price of today is $0.3936.
Applied Genetic Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Applied Genetic Technologies  (NAS:AGTC) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Applied Genetic Technologies PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Traded in Other Exchanges
N/A
Address
14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Executives
Susan Schneider officer: Chief Medical Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber officer: Chief Financial Officer C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter officer: See Remarks 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds officer: Chief Accounting Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer director, officer: President and CEO C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay officer: General Counsel C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria officer: Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad director C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v. 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v. 10 percent owner C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex officer: General Counsel C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615

Applied Genetic Technologies (Applied Genetic Technologies) Headlines

From GuruFocus

Syncona to Acquire Applied Genetic Technologies Corporation

By GlobeNewswire GlobeNewswire 10-24-2022

Syncona to Acquire Applied Genetic Technologies Corporation

By Value_Insider Value_Insider 10-24-2022